TICKERNERD
Menu
NVAXNVAXHealthcare · Biotechnology

NVAX Stock Forecast: Novavax, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.94
+6.18% on the day

The 9 Wall Street analysts covering Novavax, Inc. hold a median 12-month price target of $16 — +79.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$1.5B
Ticker Nerd rank
54 / 100
Median analyst target
$16
Analysts covering
9
Total return, dividends reinvested
1W
+11.1%
1M
+10.6%
YTD
+33.0%
1Y
+17.2%
From 52W high
−20.1%
From 52W low
+43.7%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Novavax, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Accruals
96
Quality
91
Momentum
53
Size
40
Revisions
37
Volatility
29
Growth
16
Issuance
16

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26NVAXHigh $25Median $16Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
5 Buy1 Hold3 Sell
Low $7Median $16High $25

The green dot is the last close — the median target sits +79.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 June 2026BTIGReiteratesBuy$19
6 May 2026TD CowenMaintainsHold—
27 Feb 2026HC Wainwright & Co.MaintainsBuy—
20 Jan 2026BTIGReiteratesBuy—
18 Nov 2025JP MorganMaintainsUnderweight—
10 Nov 2025B. Riley SecuritiesReiteratesBuy—
4 Nov 2025TD CowenMaintainsHold—
24 Oct 2025Cantor FitzgeraldInitiatesOverweight—
23 Oct 2025HC Wainwright & Co.MaintainsBuy—
28 Aug 2025HC Wainwright & Co.AssumesBuy$10
20 Aug 2025B of A SecuritiesDowngradeUnderperform—
22 July 2025B of A SecuritiesMaintainsNeutral—
17 June 2025CitigroupInitiatesSell—
9 May 2025JP MorganMaintainsUnderweight—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Oct 2024JefferiesMaintainsBuy$31 → $25
10 Oct 2024B. Riley SecuritiesReiteratesBuy$23 → $26
2 Oct 2024JefferiesMaintainsBuy$31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NVAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Novavax, Inc. (NVAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.6×

Cheaper than 68% of US stocks

Price / sales
3.6×

Cheaper than 36% of US stocks

Price / book
−7.7×

Cheaper than 97% of US stocks

EV / EBITDA
−10.4×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
−76.3%

Higher than 3% of US stocks

Earnings growth (YoY)
−76.3%

Higher than 5% of US stocks

Gross margin
74.9%

Higher than 87% of US stocks

Operating margin
−89.6%

Higher than 14% of US stocks

Net margin
−59.9%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−344.7%

Higher than 4% of US stocks

Return on assets
−6.5%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NVAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NVAXNovavax, Inc.$1.5B
54
ORICOric Pharmaceuticals, Inc.$1.5B
50
SLBTSL Science Holding Ltd.$1.5B
0
AVBPArrivent BioPharma, Inc.$1.4B
35
INBXInhibrx Biosciences, Inc.$1.5B
26
LBRXLB Pharmaceuticals, Inc.$1.5B
6
LTGOLatigo Biotherapeutics, Inc.$1.4B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Novavax, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVAX news & analysis

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Zacks Investment Research · 7 Aug 2026positive

Novavax reported Q2 earnings and revenue that beat estimates, and raised its 2026 adjusted revenue outlook while lowering expense guidance. The company also outlined potential milestones related to its partnership with Sanofi.

Why it matters — The earnings beat and raised 2026 revenue outlook point to improved financial expectations, while the outlined Sanofi milestones could affect future partnership-related value for Novavax watchers.

Novavax Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Novavax reported second-quarter 2026 revenue of $57 million and a net loss of $53 million. The company highlighted progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant platform, and continued cost reductions.

Why it matters — NVAX watchers would note the company's strategic collaborations, platform expansion, and cost-reduction efforts as indicators of its ongoing commercial and operational direction.

Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Novavax's Q2 2026 earnings call. The item identifies the call and its transcript but provides no details on the financial results or commentary discussed during the call.

Why it matters — A NVAX watcher would care because the earnings call transcript offers insight into the company's quarterly performance and management's outlook, both of which are key inputs for assessing the stock.

Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Novavax reported a second-quarter loss of $0.32 per share, narrower than the Zacks Consensus Estimate of a $0.36 loss, while topping revenue estimates. The result compares with earnings of $0.62 per share in the same quarter a year ago.

Why it matters — The quarter came in better than Wall Street expected on both earnings and revenue, even though it swung to a loss from a year-ago profit, giving NVAX watchers a read on the company's recent performance.

Are Medical Stocks Lagging Novavax (NVAX) This Year?

Zacks Investment Research · 6 Aug 2026neutral

A Zacks Investment Research article compares the year-to-date performance of Novavax (NVAX) and Addus HomeCare (ADUS) against their medical sector, examining how each stock has fared relative to the broader sector so far this year.

Why it matters — NVAX watchers would care because the piece directly benchmarks Novavax's performance against its sector peers, offering context on how the stock is tracking relative to the medical sector in 2024.

FAQ

Frequently asked questions about NVAX stock

What is the NVAX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Novavax, Inc. have a median 12-month price target of $16, with estimates ranging from $7 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVAX stock a buy right now?

Of the 9 analysts covering Novavax, Inc., 5 rate it a Buy, 1 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Novavax, Inc. 54 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVAX?

As at 22 Aug 2026, Novavax, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will NVAX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +79.2% from the last close, and Ticker Nerd's factor model ranks Novavax, Inc. 54 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVAX stock forecast for 2030?

No analyst covering Novavax, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $25 over the next 12 months.

How has NVAX stock performed over the past year?

Novavax, Inc. returned +17.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Novavax, Inc. do?

Novavax Inc. is a biotechnology company specializing in the discovery, development, and commercialization of recombinant vaccines to address serious infectious diseases.

What is the latest news on NVAX?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised". Novavax reported Q2 earnings and revenue that beat estimates, and raised its 2026 adjusted revenue outlook while lowering expense guidance. The company also outlined potential milestones related to its partnership with Sanofi.

Company

About Novavax, Inc.

Novavax Inc. is a biotechnology company specializing in the discovery, development, and commercialization of recombinant vaccines to address serious infectious diseases. The company focuses on using a proprietary recombinant nanoparticle technology platform combined with advanced adjuvants to generate robust immune responses. Novavax develops vaccine candidates targeting both well-established and emerging pathogens, supporting public health needs across global markets. Its operations center on research and development, clinical testing, regulatory approvals, and collaborations with health authorities and commercial partners to broaden access to its vaccines. Headquartered in Gaithersburg, Maryland, and working with international subsidiaries, Novavax plays a role in the biopharmaceutical and vaccine ecosystem by supplying protein-based vaccine options that complement other vaccine modalities. The company’s products and pipeline are directed toward preventing infectious diseases in diverse populations, including adults and potentially high-risk groups, through partnerships with governments, healthcare systems, and global health organizations.

CEO Mr. John Charles Jacobs M.B.A. · 749 employees · United States · https://www.novavax.com